- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02465268
Vaccine Therapy for the Treatment of Newly Diagnosed Glioblastoma Multiforme (ATTAC-II)
ATTAC-II: A Phase II Randomized, Blinded, and Placebo-controlled Trial of CMV RNA-Pulsed Dendritic Cells With Tetanus-Diphtheria Toxoid Vaccine in Patients With Newly-Diagnosed Glioblastoma
Study Overview
Status
Detailed Description
Dendritic cells (DC) are involved in activating, or turning-on, your body's immune system. Your immune system helps guard your body from germs, viruses, and other threats. Although dendritic cells are very strong, the number of them in the body is not high enough to cause a powerful immune response; therefore, more DC are made in a laboratory with cells collected from an individual's blood.
In this study, we will make a vaccine that we hope will educate immune cells to target the pp65 antigen, a type of immune marker in GBM, thus resulting in what we call the pp65 DC vaccine. Use of a vaccine that activates your immune system is a type of immunotherapy. It is hoped that by giving the pp65 DC vaccine as a shot under the skin, the immune system will be activated to attack tumor cells in the brain while leaving normal cells alone.
To see if the pp65 DC vaccine is effective for the treatment of GBM, subjects will be assigned to different treatment groups. Two groups of subjects will receive the pp65 DC vaccine and one group will receive a placebo.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Florida
-
Gainesville, Florida, United States, 32610
- University of Florida
-
Orlando, Florida, United States, 32806
- Orlando Health
-
-
North Carolina
-
Durham, North Carolina, United States, 27710
- Duke University Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Abbreviated Inclusion Criteria:
To be assessed at study enrollment prior to standard of care chemo-radiation therapy:
- Age ≥ 18 years.
- Histopathologically proven newly-diagnosed de novo GBM (WHO Grade IV glioma)
- The tumor must have a supratentorial component.
- Must have undergone definitive surgical resection of tumor with less than approximately 3cm x 3cm residual enhancing tumor as product of longest perpendicular planes by MRI.
- Recovery from the effects of surgery, postoperative infection, and other complications.
- Diagnostic contrast-enhanced MRI or CT scan of the brain preoperatively and postoperatively.
- Karnofsky Performance Status of ≥ 70.
- Signed informed consent.
- For females of childbearing potential, negative serum pregnancy test.
- Women of childbearing potential and male participants must be willing to practice adequate contraception throughout the study and for at least 24 weeks after the last dose of study drug.
To be assessed prior to initiation of adjuvant TMZ:
- Must have completed RT (targeted total dose of 59.4-60.0 Gy over ≤ 7 weeks) and concomitant TMZ (targeted dose of 75mg/m2/d for ≤ 49 days) therapy without significant toxicity that persisted over 4 weeks.
- History & physical with neurologic examination prior to initiation of adjuvant TMZ.
- For patients receiving steroids, daily dose must be ≤ 4 mg.
- CBC with differential with adequate bone marrow function.
- Adequate renal function.
- Adequate hepatic function.
Abbreviated Exclusion Criteria:
To be verified in order to randomize subject:
- Prior invasive malignancy unless disease free for ≥ 3 years.
- Metastases detected below the tentorium or beyond the cranial vault and leptomeningeal involvement.
- Recurrent or multifocal malignant gliomas.
- HIV, Hepatitis B, or Hepatitis C seropositive.
- Known active infection or immunosuppressive disease.
- Prior chemotherapy or radiosensitizers (including Gliadel wafers) for cancers of the head and neck region.
- Prior radiotherapy to the head or neck, resulting in overlap of radiation fields.
- Severe, active co-morbidity.
- Pregnancy or women of childbearing potential and men who are sexually active and not willing/able to use medically acceptable forms of contraception for the entire study period.
- Pregnant or lactating women.
- Prior allergic reaction to temozolomide, GM-CSF or Td.
- Prior history of brachial neuritis or Guillain-Barré syndrome.
- Patients treated on any other therapeutic clinical protocols within 30 days prior to study entry.
To be assessed prior to initiation of adjuvant TMZ:
- Did not start radiation therapy and temozolomide within 7 weeks of surgery.
- Progression of disease as defined by modified RANO criteria.
- More than 45 days after completion of radiation therapy and temozolomide
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: pp65-shLAMP DC with GM-CSF and Td
Given under the skin at day 22-24 after the first temozolomide cycle then at 2 week intervals.
Doses 4-10 will be given on day 22-24 of each temozolomide cycle.
Doses will continue until a total of 10 or until progression or unacceptable toxicity.
|
Other Names:
All subjects will receive a Td booster before study drug dose #1.
Subjects in the experimental arms will receive Td skin prep before study drug doses #3, #6, and #9.
Other Names:
|
Experimental: pp65-flLAMP DC with GM-CSF and Td
Given under the skin at day 22-24 after the first temozolomide cycle then at 2 week intervals.
Doses 4-10 will be given on day 22-24 of each temozolomide cycle.
Doses will continue until a total of 10 or until progression or unacceptable toxicity.
|
All subjects will receive a Td booster before study drug dose #1.
Subjects in the experimental arms will receive Td skin prep before study drug doses #3, #6, and #9.
Other Names:
Other Names:
|
Placebo Comparator: unpulsed PBMC and Saline
Given under the skin at day 22-24 after the first temozolomide cycle then at 2 week intervals.
Doses 4-10 will be given on day 22-24 of each temozolomide cycle.
Doses will continue until a total of 10 or until progression or unacceptable toxicity.
|
Other Names:
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Change in median overall survival
Time Frame: From date of randomization until the date of death, assessed up to 24 months
|
From date of randomization until the date of death, assessed up to 24 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Changes in immune response
Time Frame: Change between baseline and vaccine #3, assessed up to 4 weeks
|
Parameters include ELISPOT for evaluation of cellular immune responses is a sensitive detection assay for evaluation of antigen specific cytokine producing T cells
|
Change between baseline and vaccine #3, assessed up to 4 weeks
|
Change in progression-free survival
Time Frame: From randomization until first documentation of either disease progression or recurrence assessed up to 24 months
|
From randomization until first documentation of either disease progression or recurrence assessed up to 24 months
|
|
Changes in immune response
Time Frame: Change between baseline and vaccine #3, assessed up to 4 weeks
|
Parameters include peak antibody titers to the CMV pp65, reported as humoral response to the specific antigens.
|
Change between baseline and vaccine #3, assessed up to 4 weeks
|
Changes in immune response
Time Frame: Change between baseline and vaccine #3, assessed up to 4 weeks
|
Parameters include Cytokine Bead Array analysis to detect multiple cytokines secreted by lymphocytes after in vitro stimulation with specific and control antigens, examine the spectrum of Type 0,1,2, and 3 cytokines secreted by T cells after stimulation with overlapping peptides spanning CMV pp65, PHA, and control peptides
|
Change between baseline and vaccine #3, assessed up to 4 weeks
|
Changes in immune response
Time Frame: Change between baseline and vaccine #3, assessed up to 4 weeks
|
Parameters include cytokine flow cytometric analysis which involves the rapid early detection and analysis of the production of IFN, TNF, and IL-2 prior to cellular secretion following antigen-specific stimulation in vitro as determined by CFC
|
Change between baseline and vaccine #3, assessed up to 4 weeks
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Study Chair: Duane Mitchell, MD, PhD, University of Florida
- Principal Investigator: Maryam Rahman, MD, University of Florida
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms, Glandular and Epithelial
- Neoplasms, Neuroepithelial
- Neuroectodermal Tumors
- Neoplasms, Germ Cell and Embryonal
- Neoplasms, Nerve Tissue
- Glioblastoma
- Glioma
- Astrocytoma
- Physiological Effects of Drugs
- Antineoplastic Agents
- Immunologic Factors
- Sargramostim
- Molgramostim
Other Study ID Numbers
- IRB201400697-N
- R01CA175517 (U.S. NIH Grant/Contract)
- OCR14127 (Other Identifier: Universiy of Florida)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Glioblastoma
-
Celldex TherapeuticsCompletedGlioblastoma | Gliosarcoma | Recurrent Glioblastoma | Small Cell Glioblastoma | Giant Cell Glioblastoma | Glioblastoma With Oligodendroglial Component | Relapsed GlioblastomaUnited States
-
Juan M Garcia-GomezHospital Universitario 12 de Octubre; Hospital Clínico Universitario de ValenciaRecruitingGlioblastoma | Glioblastoma Multiforme | High Grade Glioma | Astrocytoma, Grade IV | Glioblastoma, IDH-mutant | Glioblastoma, IDH-wildtype | Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype | Glioblastoma IDH (Isocitrate Dehydrogenase) MutantSpain
-
Jasper GerritsenMassachusetts General Hospital; Universitaire Ziekenhuizen KU Leuven; University... and other collaboratorsRecruitingGlioblastoma | Glioblastoma Multiforme | Glioblastoma, IDH-wildtype | Glioblastoma Multiforme, Adult | Glioblastoma Multiforme of BrainUnited States, Belgium, Switzerland, Germany, Netherlands
-
Jasper GerritsenMassachusetts General Hospital; Universitaire Ziekenhuizen KU Leuven; University... and other collaboratorsRecruitingGlioblastoma | Glioblastoma Multiforme | Recurrent Glioblastoma | Glioblastoma, IDH-wildtype | Glioblastoma Multiforme, Adult | Glioblastoma Multiforme of Brain | Astrocytoma of Brain | Astrocytoma, MalignantUnited States, Germany, Netherlands, Switzerland, Belgium
-
Northwestern UniversityAgenus Inc.; CarTheraRecruitingGlioblastoma Multiforme | Gliosarcoma | Newly Diagnosed Glioblastoma | Glioblastoma, Isocitric Dehydrogenase (IDH)-WildtypeUnited States
-
Milton S. Hershey Medical CenterRecruitingGlioblastoma | Glioblastoma Multiforme | Glioblastoma Multiforme, Adult | Glioblastoma Multiforme of BrainUnited States
-
Leland MethenyNational Cancer Institute (NCI)RecruitingGlioblastoma Multiforme | Supratentorial Gliosarcoma | Glioblastoma Multiforme, Adult | Supratentorial GlioblastomaUnited States
-
University Hospital, GenevaActive, not recruitingGlioblastoma Multiforme | Glioblastoma Multiforme of Brain | Glioma of Brain | Glioblastoma, AdultSwitzerland
-
Celldex TherapeuticsCompletedGlioblastoma | Gliosarcoma | Small Cell Glioblastoma | Giant Cell Glioblastoma | Glioblastoma With Oligodendroglial ComponentUnited States, Canada, Australia, Israel, Taiwan, United Kingdom, Belgium, France, Spain, Germany, Austria, Brazil, Colombia, Czechia, Greece, Hungary, India, Italy, Mexico, Netherlands, New Zealand, Peru, Switzerland, Thailand
-
Northwestern UniversityNational Cancer Institute (NCI)RecruitingGlioblastoma | Astrocytoma | Recurrent Glioblastoma | MGMT-Unmethylated Glioblastoma | Glioblastoma, IDH-WildtypeUnited States
Clinical Trials on Saline
-
Vanderbilt University Medical CenterActive, not recruitingPostural Tachycardia SyndromeUnited States
-
Johns Hopkins UniversityCystic Fibrosis FoundationCompletedCystic Fibrosis
-
University Hospital Inselspital, BerneCompletedCardiovascular Diseases | Valvular Heart DiseaseSwitzerland
-
Aalborg UniversityThe Danish Rheumatism AssociationCompleted
-
Imam Abdulrahman Bin Faisal UniversityUnknownOtorhinolaryngologic Diseases | RhinosinusitisSaudi Arabia
-
Qassim UniversityCompletedApical Periodontitis | Post Operative Pain | Dental Pulp NecrosesSaudi Arabia
-
Dr. Michael FlavinWithdrawn
-
Szpital im. Św. Jadwigi ŚląskiejRecruiting
-
Makassed General HospitalCompletedLength of Hospital StayLebanon
-
University of Washington, the Collaborative Health...Cystic Fibrosis FoundationCompleted